Durham, North Carolina, November 2025 Accord BioPharma has announced FDA approval of two denosumab biosimilars, OSVYRTI (denosumab-desu) and JUBEREQ (denosumab-desu), representing a significant expansion in US access to biologic therapies that support bone health in both cancer and osteoporosis populations. The approval underscores the increasing maturity of the US biosimilar landscape and reflects the growing demand for affordable, high-value biologics.
Science Significance
Developing a biosimilar to denosumab requires precise engineering of a monoclonal antibody capable of binding the RANKL ligand with identical affinity and biological activity. OSVYRTI and JUBEREQ underwent extensive analytical comparison covering structure, glycosylation patterns, receptor binding, and pharmacokinetic behaviour. Clinical testing confirmed that both biosimilars demonstrated no clinically meaningful differences from the reference product in terms of safety, immunogenicity, and therapeutic effect. The scientific achievement reflects significant advancements in antibody development and manufacturing processes, supporting the broader acceptance of biosimilars as reliable therapeutic options in complex medical conditions.
Regulatory Significance
FDA approval affirms compliance with the standards set by the Biologics Price Competition and Innovation Act, which governs biosimilar development in the United States. The agency’s decision demonstrates confidence in the robustness of Accord’s development program and opens the door for potential future applications, including interchangeability status pending additional studies. The approval enhances the credibility of biosimilars in the US market and positions Accord as a leader in the next wave of monoclonal antibody biosimilar introductions. It also supports the FDA’s strategic objective of expanding biologic competition to improve healthcare affordability.
Advertisement
Business Significance
For Accord BioPharma, the approval strengthens its US commercial portfolio and introduces significant opportunities in the oncology and osteoporosis treatment markets. Denosumab is widely used in hospitals, oncology practices, infusion centres, and specialty clinics, creating substantial market demand. The availability of two biosimilar brands enables tailored commercial strategies across diverse healthcare settings. Payers are increasingly supportive of biosimilars due to their ability to reduce costs while maintaining clinical quality, positioning Accord for significant adoption and competitive advantage in a growing biologics market.
Patients Significance
Thousands of cancer patients rely on denosumab to prevent bone destruction caused by metastasis, while millions more use the therapy to manage osteoporosis. The introduction of biosimilars offers more affordable and accessible options, reducing the financial burden on patients and improving long-term adherence. Access to high-quality bone-protective therapy is essential for preventing fractures, maintaining mobility, reducing hospitalization risks, and supporting overall quality of life. Accord’s biosimilars represent a crucial step toward ensuring that more patients can initiate and continue treatment without cost-related interruptions.
Policy Significance
The approval of OSVYRTI and JUBEREQ aligns with US health-policy initiatives aimed at promoting biosimilar market expansion to reduce drug costs and enhance treatment equity. Government agencies and policymakers continue to emphasize the importance of biosimilars in creating a more resilient and sustainable healthcare system.
The decision supports federal goals of improving competition in specialty-drug categories and demonstrates how biosimilars play a pivotal role in balancing innovation with affordability.
The FDA’s approval of Accord BioPharma’s denosumab biosimilars marks a major advancement in expanding access to essential bone-health therapies. Through strong scientific development, regulatory compliance, and patient-focused innovation, Accord is helping shape the future of biologic medicine in the United States. OSVYRTI and JUBEREQ stand as important additions to the therapeutic arsenal, offering clinicians and patients reliable options that support better outcomes and greater treatment accessibility.
Source: Accord BioPharma press release
